Connect
MJA
MJA

The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure

Philip M Clarke
Med J Aust 2013; 198 (5): 260. || doi: 10.5694/mja12.11439
Published online: 18 March 2013

To the Editor: Following two articles in the Journal,1,2 I wish to provide an update on the pricing of statins in Australia and the implications for Pharmaceutical Benefits Scheme (PBS) expenditure. I was prompted to do so by a recent review by the Pharmaceutical Benefits Advisory Committee (PBAC), which was instigated by the Senate when it passed legislation enabling the current pharmaceutical pricing arrangements.3 The purpose of the review was to determine if there was new evidence on whether rosuvastatin and atorvastatin should be included in the existing statins therapeutic group.

  • Philip M Clarke

  • School of Population Health, University of Melbourne, Melbourne, VIC.


Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.